Strategies for management of relapsed or refractory hodgkin lymphoma

Leo I. Gordon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The advent of effective therapies has improved outcomes for those with newly diagnosed Hodgkin lymphoma (HL), with a resulting cure rate of at least 80%. However, with limited data on therapeutic options in the setting of advanced disease, individualized treatment is recommended, and potential long-term effects of therapy remain a key consideration. At the NCCN 22nd Annual Conference, Dr. Leo I. Gordon explored strategies for systemic therapy in the relapsed or refractory setting, focusing primarily on the standard of high-dose therapy/ autologous stem cell rescue, the CD30-targeted antibody drug conjugate brentuximab vedotin, and checkpoint inhibition.

Original languageEnglish (US)
Pages (from-to)716-718
Number of pages3
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5S
DOIs
StatePublished - May 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Strategies for management of relapsed or refractory hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this